Cardiac Pathways Announces Reduction in Force.SUNNYVALE, Calif.--(BW HealthWire)--March 11, 1999--Cardiac Pathways Corp. (Nasdaq:CPWY) today announced a reduction in force of approximately 25% of its current employees. The workforce reductions were company-wide and were made to further reduce operating spending and to align available resources and operations. In February 1999, the company implemented a 15% reduction in force. The company will record an aggregate charge of approximately $225,000 related to these actions during the quarter ended March 31, 1999. Cardiac Pathways designs, develops and manufactures minimally invasive systems to diagnose diagnose /di·ag·nose/ (di´ag-nos) to identify or recognize a disease. di·ag·nose v. 1. To distinguish or identify a disease by diagnosis. 2. and treat cardiac tachyarrhythmias (abnormally rapid heart rhythms Noun 1. heart rhythm - the rhythm of a beating heart cardiac rhythm regular recurrence, rhythm - recurring at regular intervals atrioventricular nodal rhythm, nodal rhythm - the normal cardiac rhythm when the heart is controlled by the ). The company is a pioneer and leader in the development of complete, integrated mapping and ablation ablation /ab·la·tion/ (-shun) 1. separation or detachment; extirpation; eradication. 2. removal or destruction, especially by cutting. ab·la·tion n. systems for the diagnosis and treatment of heart rhythm disturbances. This release contains certain forward-looking statements forward-looking statement A projected financial statement based on management expectations. A forward-looking statement involves risks with regard to the accuracy of assumptions underlying the projections. that involve risks and uncertainties. Actual results could differ materially from those anticipated in these forward-looking statements as a result of certain factors, including the company's success in manufacturing the product in commercial quantities, developing an effective marketing and distribution channel for the product and creating market acceptance of the product versus alternative therapies or products, as well as completing any remaining development of its other products, the efficacy and safety of the products in the laboratory, clinical and other testing, the uncertainties relating to relating to relate prep → concernant relating to relate prep → bezüglich +gen, mit Bezug auf +acc FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. and other regulatory approvals, and additional factors. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion